NASDAQ:EKSO - Nasdaq - US2826443010 - Common Stock - Currency: USD
EKSO BIONICS HOLDINGS INC
NASDAQ:EKSO (2/11/2025, 11:35:56 AM)
0.5626
-0.01 (-1.3%)
The current stock price of EKSO is 0.5626 USD. In the past month the price decreased by -27.17%. In the past year, price decreased by -71.83%.
Move expected to broaden access to Ekso Bionics’ portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges...
SAN RAFAEL, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton...
SAN RAFAEL, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton...
SAN RAFAEL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.04 | 227.13B | ||
ISRG | INTUITIVE SURGICAL INC | 80.58 | 210.38B | ||
BSX | BOSTON SCIENTIFIC CORP | 42.04 | 155.50B | ||
SYK | STRYKER CORP | 32.12 | 149.26B | ||
MDT | MEDTRONIC PLC | 17.4 | 117.12B | ||
BDX | BECTON DICKINSON AND CO | 17.33 | 66.14B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.58 | 41.86B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.69 | 39.88B | ||
IDXX | IDEXX LABORATORIES INC | 41.2 | 37.95B | ||
RMD | RESMED INC | 26.93 | 34.94B | ||
DXCM | DEXCOM INC | 51.26 | 34.04B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 20.91 | 26.14B |
Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 70 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves multiple markets and can be utilized both by able-bodied persons and persons with physical disabilities or impairments. Its products include EksoNR, which is a wearable robotic exoskeleton specifically designed to be used in a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower-limb powered exoskeleton; Ekso Indego Personal is a lightweight powered lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The firm enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate and to walk again; assist individuals with a range of upper extremity impairments and allow industrial workers to perform difficult repetitive work for extended periods. Its segments include EksoHealth and EksoWorks.
EKSO BIONICS HOLDINGS INC
101 Glacier Point, Suite A
San Rafael California CALIFORNIA 94804 US
CEO: Jack Peurach
Employees: 71
Company Website: https://eksobionics.com/
Investor Relations: https://ir.eksobionics.com/
Phone: 15109841761
The current stock price of EKSO is 0.5626 USD.
The exchange symbol of EKSO BIONICS HOLDINGS INC is EKSO and it is listed on the Nasdaq exchange.
EKSO stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for EKSO, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of EKSO.
EKSO does not pay a dividend.
EKSO will report earnings on 2025-02-27, after the market close.
EKSO does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).
The outstanding short interest for EKSO is 7.32% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by 41.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -38.11% | ||
ROE | -74.86% | ||
Debt/Equity | 0.28 |
ChartMill assigns a Buy % Consensus number of 83% to EKSO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 53.64% and a revenue growth -1.84% for EKSO